Current global health developments include China's green light for foreign-owned hospitals, the addition of AstraZeneca's ...
AstraZeneca and Daiichi Sankyo’s breast cancer drug Enhertu to join China’s state health insurance in 2025, enhancing ...
The new 1.1 billion-yuan ($152 million) production facility in Shanghai will make antibody-drug conjugates, which use ...
The U.S. pharmaceutical industry seeks to alter Medicare drug price negotiation laws under Trump's return. China approves ...
China: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance ...
which was cleared in China for TNBC in 2022. The approval means Kelun has brought its TROP2 ADC to market ahead of ...
AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK ...
(RTTNews) - HUTCHMED (China) Limited (?HCM) announced that following the contract renewal with the China National Healthcare Security Administration ("NHSA"), the updated National Reimbursement Drug ...
AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...
AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...
China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance, a move ...
AstraZeneca's Fasenra, an injectable treatment for severe asthma, is more effective during attacks than the oral steroid that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback